Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited, commonly referred to as Alembic, is a prominent player in the global pharmaceutical industry, headquartered in Vadodara, India. Established in 1907, the company has a rich history marked by significant milestones, including its expansion into regulated markets and the development of a robust portfolio of generic and branded formulations.
Alembic operates primarily in the areas of pharmaceuticals, biotechnology, and active pharmaceutical ingredients (APIs), focusing on therapeutic segments such as cardiovascular, anti-infective, and central nervous system disorders. The company is renowned for its commitment to quality and innovation, which is reflected in its extensive range of products that meet stringent international standards.
With a strong market position, Alembic Pharmaceuticals has achieved notable success, including multiple approvals from regulatory authorities worldwide. Its dedication to research and development, coupled with a strategic approach to global expansion, solidifies its reputation as a trusted name in the pharmaceutical sector.
+36 vs industry average
Alembic Pharmaceuticals’s score of 74 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Alembic Pharmaceuticals?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Alembic Pharmaceuticals's reported carbon emissions
In 2025, Alembic Pharmaceuticals reported total greenhouse gas emissions of approximately 761.2 million kg CO2e. This includes 80.3 million kg CO2e from Scope 1, 77.9 million kg CO2e from Scope 2, and 602.9 million kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its greenhouse gas emissions by 63% across all scopes by FY2034, using FY2022 as the base year. Furthermore, Alembic aims for a significant long-term reduction of 90% by FY2050, also from the FY2022 baseline. Alembic Pharmaceuticals is committed to achieving net-zero emissions by FY2050, aligning its targets with the Science Based Targets initiative (SBTi) to ensure that its emissions reductions are consistent with the global goal of limiting warming to 1.5°C. The company’s climate strategy encompasses all scopes of emissions, reflecting a comprehensive approach to sustainability in the pharmaceutical sector.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Alembic Pharmaceuticals’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Alembic Pharmaceuticals yet.
Scope 3 top emissions categories
12 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsFrequently asked questions
Common questions about Alembic Pharmaceuticals’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project